GERN logo Geron : GERN

GERN

Stock Data

$1.41

Change up

$0.07 (5.22%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Geron Corp is a biopharmaceutical company focused on developing treatments for blood cancers. Its main project, imetelstat, is a groundbreaking therapy aimed at stopping the spread of cancerous cells in certain blood disorders. This innovative drug is currently in advanced testing stages, showing promise for patients with specific types of myelodysplastic syndromes and myelofibrosis. Founded in 1990 and based in Foster City, California, Geron is at the forefront of research in telomerase inhibition, a novel approach in cancer treatment.

All Geron Articles

78 Articles

1 2 3 6

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.